INTRODUCTION {#s1}
============

Osteosarcoma (OS) is the most common primary malignant bone tumor, usually occurring in the second decade of life. The advent of chemotherapy in nonmetastatic OS has dramatically improved the 5-year event-free survival from \< 20% to 60% to 70%, although not much has changed in the last three decades.^[@B1]^ The four most active chemotherapeutic drugs used in OS are methotrexate, cisplatin, doxorubicin, and ifosfamide. After an initial period of intense skepticism, high-dose methotrexate (HDMtx) regimens, eg, MAP (methotrexate, adriamycin, and cisplatin), have become standard of care in North America and Europe.^[@B2]^ As of now, the question of using non-HDMtx--based regimens is no more pertinent for Western settings and is not a priority for ongoing research.^[@B3]^ There exists a lack of clarity in regard to how and which combinations to use, especially in the setting of a resource-limited country such as India, and there is insufficient evidence of these practices. In this article, we focused on the current standard of care vis-a-vis the chemotherapy of practical choice in a resource-constrained environment to provide the best benefit in the interest of patients.

WHY IS AN HDMtx-CONTAINING TRIPLE REGIMEN (MAP) THE STANDARD OF CARE? {#s2}
=====================================================================

The use of a triple regimen containing HDMtx, doxorubicin, and cisplatin (MAP; as was used in the control arm of the recently published European and American Osteosarcoma Study Group \[EURAMOS\]-1 trial^[@B4]^) is the standard of care in most developed nations. The HDMtx-based regimen is widely used, but it is surprising to note that there are no head-to-head randomized trials proving its superior efficacy to a non-HDMtx--containing regimen.

The history of HDMtx in OS is interesting and is replete with both positive and negative trials. Initial enthusiasm as a result of good response rates and outcomes was dampened by a controlled trial by the Mayo Clinic comparing HDMtx and amputation versus amputation only; this study showed that there was no apparent improvement with the administration of HDMtx.^[@B5]^ However, this study had a small sample size of only 38 patients, and the dose of HDMtx used was \< 8 gm/m^2^. Subsequently, a two-arm randomized trial, the Multi-Institutional Osteosarcoma Study, used surgical ablation and HDMtx-based chemotherapy (MAP) in one arm and surgical ablation only in the other (control) arm; an unforeseen benefit in the chemotherapy arm was reported.^[@B6]^ It is difficult to pinpoint the chemotherapy drug responsible for the success, because all of these drugs have good activity as single agents. The efficacy of HDMtx was finally accepted, but with variable enthusiasm. However, the search continued thereafter for the optimal regimen.

In the only randomized trial conducted to test three drugs versus a two-drug regimen, patients in the European Osteosarcoma Intergroup trial were randomly assigned to a cisplatin plus doxorubicin backbone with or without HDMtx.^[@B7]^ There was a disease-free survival benefit with the cisplatin and doxorubicin--containing regimen, but no difference in the overall survival between these regimens. However, this study has been criticized for the inadequate dose of HDMtx (8 gm/m^2^ compared with the current standard dose of 12 gm/m^2^) and lower dose intensity, with fewer cycles of cisplatin and doxorubicin in the arm with HDMtx. In a subsequent European Osteosarcoma Intergroup study, the inclusion of methotrexate in a multidrug arm (HDMtx, doxorubicin, bleomycin, cyclophosphamide, dactinomycin, vincristine, and cisplatin) did not show any advantage compared with two-drug regimens (cisplatin and doxorubicin). This study had extremely poor compliance in the multidrug arm, a suboptimal methotrexate dose (8 gm/m^2^), and overall poor outcomes in both arms. In addition, in the multidrug arm it included drugs such as actinomycin D and bleomycin, which had limited activity in OS.^[@B8]^ After the poor outcomes in the latter trial, two-drug regimens went out of favor and were minimally used in further trials.

Because randomized trials were not able to answer this question, the answer was sought through meta-analyses. van Dalen et al^[@B9]^ published a Cochrane meta-analysis suggesting that there is not enough evidence to approve or disapprove use of HDMtx in OS. Another meta-analysis by Anninga et al^[@B10]^ showed that regimens containing at least three drugs (including methotrexate plus adriamycin plus cisplatin \[plus ifosfamide; MAP(Ifo)\]) had significantly better outcomes than two-drug regimens, but there was no significant difference between MAP and MAP(Ifo) (or MAP plus etoposide). This meta-analysis, however, contained only two phase III randomized studies that compared regimens with HDMtx and a non-HDMtx regimen, the outcome of which was negative.

Thus the use of HDMtx is largely supported by phase II studies and the vast experience that centers have with use of this regimen, rather than from randomized controlled trials comparing HDMtx- with non-HDMtx--containing regimens; hence its benefit is not an unquestionable fact. The recent use of HDMtx-containing regimens in randomized trials gives more certainty and reliability regarding the efficacy of methotrexate and may be the reason why non-HDMtx regimens are not often used in clinical trials.^[@B11],[@B12]^ To our knowledge, there has been no randomized trial to compare non-HDMtx triple-drug therapy with HDMtx-containing triple-drug therapy such as ifosfamide, adriamycin, and cisplatin.

WHY HDMtx CHEMOTHERAPY IS NOT CUT OUT FOR INDIAN SCENARIOS {#s3}
==========================================================

The use of HDMtx requires admission, rigorous hydration, and leucovorin rescue with the associated toxicities. In most of the tertiary care hospitals in India, the logistic issues do not allow administration of HDMtx because of difficulty in inpatient admissions (and associated cost) and lack of facilities to measure methotrexate levels. HDMtx is associated with a 4% risk of renal failure, and an associated 2% mortality risk in developed countries.^[@B13]^ This is compounded by the fact that most of the hospitals in India do not have hemodialysis facilities for timely discovery of the most-feared toxicity of HDMtx---renal failure. Furthermore, carboxypeptidase G2, which is the rescue drug for methotrexate intoxication, is not available in India. This emphasizes the need for chemotherapy according to the available resources, without compromising efficacy and with the least possible long- and short-term toxicity.

RISE OF NON-HDMtx--CONTAINING THREE-DRUG REGIMENS {#s4}
=================================================

In light of the above-mentioned problems, non-HDMtx--containing regimens have been frequently used in resource-constrained settings. In recent years, there has been an upsurge in the use and thus publications of non-HDMtx--containing three-drug regimens, with good outcomes in nonmetastatic OS. The majority of studies with non-HDMtx regimens used a backbone of cisplatin and doxorubicin with ifosfamide or cyclophosphamide ([Table 1](#T1){ref-type="table"}). These studies have small sample sizes and variable lengths of follow-up. In the largest of these trials, a multi-institutional study by Daw et al,^[@B14]^ doxorubicin and ifosfamide were combined with carboplatin instead of cisplatin, with a resultant 5-year event-free survival rate of 66%. This compares favorably with the outcome seen in an HDMtx-containing chemotherapy regimen.^[@B11]^ Furthermore, good outcomes with carboplatin need further trials to confirm its activity as part of a multidrug regimen. It would also decrease the need for hydration (as in cisplatin therapy) and lessen the risks of electrolyte imbalance, nephrotoxicity, and hearing loss. Therefore, in given conditions, an optimal level of care can be delivered by giving multidrug chemotherapy that includes carboplatin, adriamycin, and ifosfamide as backbone. However, it needs further confirmation in a larger sample size.
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DOES THE ADDITION OF A FOURTH DRUG ADD BENEFIT TO A THREE-DRUG REGIMEN? {#s5}
=======================================================================

Regarding the addition of ifosfamide to MAP chemotherapy (ie, four-drug chemotherapy), it seems that there is no benefit, as shown by the randomized control trial, Intergroup Study 0133.^[@B11]^ This finding was further supported by the meta-analysis by Anninga et al.^[@B10]^ Thus, currently there is no beneficial role of adding ifosfamide to MAP chemotherapy.

DO WE NEED TO CHANGE CHEMOTHERAPY ON THE BASIS OF HISTOLOGIC RESPONSE TO NEOADJUVANT CHEMOTHERAPY? {#s6}
==================================================================================================

Percentage necrosis assessment after neoadjuvant chemotherapy is one of the most robust prognostic markers for survival outcome in nonmetastatic OS.^[@B15],[@B16]^ Those patients who have \> 90% necrosis have a 5-year event-free survival rate of approximately 70% to 80% vis-a-vis 40% to 60% in those with \< 90% necrosis.^[@B16],[@B17]^ There have been several attempts to change the treatment on the basis of response to chemotherapy. The most successful of these has been the addition of ifosfamide and etoposide in poor responders, which has been shown to improve outcomes in phase II studies.^[@B18]^ The EURAMOS trial addressed this question by randomly assigning the high-risk group to continuation of MAP with or without ifosfamide and etoposide. The recently published results of the EURAMOS-1 trial show that the addition of ifosfamide and etoposide in poor responders increased toxicity without any significant benefit.^[@B12]^ Furthermore, these patients reported higher rates of second malignant neoplasm and were less likely to complete therapy. This question has not been adequately addressed in patients receiving nonmethotrexate-based regimens. But we do not think that such a collaboration to answer this question is possible in the near future.

INDIAN DATA: LESSONS TO LEARN {#s7}
=============================

Recently, Nataraj et al^[@B19]^ published data for nonmetastatic OS treated with a non-HDMtx regimen in 237 patients from a tertiary care center. Patients received three cycles of neoadjuvant cisplatin and doxorubicin and underwent local surgery. On the basis of percentage necrosis, they received either three cycles of cisplatin and doxorubicin (if necrosis was \> 90%) or they received ifosfamide and etoposide alternated with cisplatin and doxorubicin for the next eight cycles if they were poor responders. Thus a few patients received a two-drug regimen (25%), whereas the remaining received a four-drug regimen. After a median follow-up of 30 months, event-free survival and overall survival rates at 5 years were 36% and 50%, respectively. In addition, necrosis did not prove to be a prognostic factor for the final outcome. Such outcomes can be explained by an unusually large tumor size, the inclusion of patients with poor performance status, the use of non-HDMtx--based chemotherapy, or the use of double-drug therapy. The absence of necrosis as a prognostic factor could be explained by the complex and time-consuming method (including decalcification and meticulous pathologic assessment), and thus might lack accuracy in locations that do not have sarcoma pathologists. In a disease such as OS, the quality and timing of surgery should also be evaluated in detail, because surgery is as important as chemotherapy in deciding the outcome. However, all of these factors need to be systematically addressed in a prospective study. Another problem that emerged in the study was that the abandonment rate was approximately 20%, which underscores the fact that in India we have different issues to deal with. In the future, the focus of ongoing research in developing countries should also include the potential requirement of having a strong referral system and improved ancillary services, which is the stepping stone for improved outcomes in OS.

WHAT NEEDS TO BE DONE? TRIALS AND COLLABORATIONS DIRECTED TO LOCAL NEEDS {#s8}
========================================================================

There is an urgent need to study non-HDMtx regimens in India or other developing countries with limited resources for feasibility, response rates, toxicities (both long term and short term), and survival outcome in a prospective fashion. In addition, only an adequately powered randomized trial comparing a methotrexate-containing and a nonmethotrexate-containing regimen (preferably using a three-drug regimen for both) will be able to solve the conundrum of the ideal regimen to use in a resource-constrained setting. Second, in places where double-drug therapy is still the regimen of choice, a well-conducted randomized study could address the question of double- versus three-drug therapy. We can take a cue from recent publications that in the developing world, the choice of an appropriate control can be according to local policies and resources and cannot be copied from those used in the developed world.^[@B20]^ However, it would require a large sample size and plenty of collaboration. This might be possible only by a EURAMOS-like collaboration between the largest centers in the country. Because this remains the only hope for our patients with OS, we must not forget:

> "Unity is strength\...when there is teamwork and collaboration, wonderful things can be achieved."
>
> ---Mattie Stepanek
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